DUBLIN, Sept. 15, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Heart Defect Closure Devices Market 2014-2018" report to their offering.
http://photos.prnewswire.com/prnh/20130307/600769
Heart defect closure devices are used for the treatment of several CHDs. The heart closure devices help when closing the ostium/ hole/ deficiency in the structure of the heart present in the septal walls or blood vessels that occurs in the patients with CHDs. CHD is an anomaly in the structure of the heart present at the time of birth, which are among the most common types of birth defects.
Some of the CHDs include ASD, PFO, VSD, PDA and LAA. These defects cause disruption of the normal flow of blood through the heart. CHDs can happen because of incomplete or abnormal development of the heart of the fetus in the womb during the very early weeks of pregnancy.
The analysts forecast the Global Heart Defect Closure Devices market will grow at a CAGR of 9 percent over the period 2013-2018.
The Global Heart Defect Closure Devices market can be categorized into segments on the basis of heart defects: Atrial Septal Defect, Left Atrial Appendage, Patent Foramen Ovale, Patent Ductus Arteriosus, and Ventricular Septal Defect.
The report, the Global Heart Defect Closure Devices Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Heart Defect Closure Devices market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
There is a high risk of stroke in atrial fibrillation patients. Anticoagulant medication therapy is the most common approach for stroke prevention. However, with advances in technology, there has been an increase in the use of LAA closure devices for stroke prevention in atrial fibrillation patients. Since embolic strokes originate from LAA, these devices offer an alternative to pharmacological drug therapy using drugs such as Warfarin or Dabigatra
According to the report, the Global Heart Defect Closure Devices market is driven by several factors, of which an increase in the incidence of CHDs among the pediatric population worldwide is one of the major drivers. This has led to an increase in demand for heart defect closure devices for the treatment of CHDs such as ASD, VSD, PFO, PDA, and LAA. Other major factors contributing to the demand for heart defect closure devices are high adoption of MRI procedures and increasing use of chemotherapy.
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Market Research Methodology
05. Introduction
06. Market Landscape
07. Market Segmentation by Application
08. Regulatory Approvals for Heart Defect Closure Devices
09. Geographical Segmentation
10. Key Leading Countries
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
19. Key Vendor Analysis
20. Other Reports in this Series
Companies Mentioned:
- Boston Scientific Corp.
- St. Jude Medical Inc.
- W.L. Gore and Associates Inc.Other Prominent Vendors
- Biosense Webster
- Cardia Inc.
- LifeTech Scientific
- Maquet Cardiovascular
- Medtronic
- Occlutech Holding AG
- Pfm medical
- Starway Medical Technology
- Terumo Cardiovascula
For more information visit http://www.researchandmarkets.com/research/mr953n/global_heart
Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net
